연구동향 분석
박사

Development of poly(mannitol-co-PEI) gene transporter modified with rabies virus glycoprotein for brain targeted delivery of therapeutic siRNA : 광견병 바이러스 당단백질로 수식된 뇌 표적 치료용 폴리만니톨계 siRNA 전달체의 개발

박태은 2015년

논문상세정보
인용/피인용
' Development of poly(mannitol-co-PEI) gene transporter modified with rabies virus glycoprotein for brain targeted delivery of therapeutic siRNA : 광견병 바이러스 당단백질로 수식된 뇌 표적 치료용 폴리만니톨계 siRNA 전달체의 개발' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • alzheimer’s disease
  • bace1
  • blood-brain barrier
  • caveolar endocytosis
  • mannitol
  • polyethylenimine
  • rna interference
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
366 0

0.0%

' Development of poly(mannitol-co-PEI) gene transporter modified with rabies virus glycoprotein for brain targeted delivery of therapeutic siRNA : 광견병 바이러스 당단백질로 수식된 뇌 표적 치료용 폴리만니톨계 siRNA 전달체의 개발' 의 참고문헌

  • van Meer, G. and Simons, K. 1986. The function of tight junctions inmaintaining differences in lipid composition between the apical and thebasolateral cell surface domains of MDCK cells. EMBO J. 5(7), 1455-1464.
  • de Boer, A. G. and Gaillard, P. J. 2007. Drug targeting to the brain. Annu RevPharmacol Toxicol. 47(323-355.
  • Zhi, D., Zhang, S., Wang, B., Zhao, Y., Yang, B. and Yu, S. 2010. Transfectionefficiency of cationic lipids with different hydrophobic domains in genedelivery. Bioconjug Chem. 21(4), 563-577.
  • Zeier, Z., Aguilar, J. S., Lopez, C. M., Devi-Rao, G. B., Watson, Z. L., Baker,H. V., Wagner, E. K. and Bloom, D. C. 2009. A limited innate immuneresponse is induced by a replication-defective herpes simplex virus vectorfollowing delivery to the murine central nervous system. J Neurovirol. 15(5-6), 411-424.
  • Yla-Herttuala, S. 2012. Endgame: glybera finally recommended for approvalas the first gene therapy drug in the European union. Mol Ther. 20(10), 1831-1832.
  • Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R. andAnderson, D. G. 2014. Non-viral vectors for gene-based therapy. Nat RevGenet. 15(8), 541-555.
  • Yeo, Y. 2013. Nanoparticulate drug delivery systems : strategies, technologies,and applications. Hoboken, New Jersey, Wiley.
  • Xie, F. L., Yao, N., Qin, Y., Zhang, Q. Y., Chen, H. L., Yuan, M. Q., Tang, J.,Li, X. K., Fan, W., Zhang, Q., Wu, Y., Hai, L. and He, Q. 2012. Investigationof glucose-modified liposomes using polyethylene glycols with differentchain lengths as the linkers for brain targeting. International Journal ofNanomedicine. 7(163-175.
  • Wong, H. L., Wu, X. Y. and Bendayan, R. 2012. Nanotechnological advancesfor the delivery of CNS therapeutics. Adv Drug Deliv Rev. 64(7), 686-700.
  • Wirth, T., Parker, N. and Yla-Herttuala, S. 2013. History of gene therapy. Gene.525(2), 162-169.
  • Wirdefeldt, K., Adami, H. O., Cole, P., Trichopoulos, D. and Mandel, J. 2011.Epidemiology and etiology of Parkinson's disease: a review of the evidence.Eur J Epidemiol. 26 Suppl 1(S1-58.
  • Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O.,Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., Chen, D.,Barros, S., Klebanov, B., Novobrantseva, T., Langer, R. and Anderson, D. G.2014. Degradable lipid nanoparticles with predictable in vivo siRNA deliveryactivity. Nat Commun. 5(4277.
  • Werth, S., Urban-Klein, B., Dai, L., Hobel, S., Grzelinski, M., Bakowsky, U.,Czubayko, F. and Aigner, A. 2006. A low molecular weight fraction ofpolyethylenimine (PEI) displays increased transfection efficiency of DNAand siRNA in fresh or lyophilized complexes. J Control Release. 112(2),257-270.
  • Wang, S., Singh, R. D., Godin, L., Pagano, R. E. and Hubmayr, R. D. 2011.Endocytic response of type I alveolar epithelial cells to hypertonic stress. Am186J Physiol Lung Cell Mol Physiol. 300(4), L560-568.
  • Walker, G. F., Fella, C., Pelisek, J., Fahrmeir, J., Boeckle, S., Ogris, M. andWagner, E. 2005. Toward synthetic viruses: endosomal pH-triggereddeshielding of targeted polyplexes greatly enhances gene transfer in vitro andin vivo. Mol Ther. 11(3), 418-425.
  • Volonte, D., Galbiati, F., Pestell, R. G. and Lisanti, M. P. 2001. Cellular stressinduces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activationof p38 mitogen-activated protein kinase and c-Src kinase. Evidence forcaveolae, the actin cytoskeleton, and focal adhesions as mechanical sensorsof osmotic stress. J Biol Chem. 276(11), 8094-8103.
  • Visser, C. C., Stevanovic, S., Voorwinden, L. H., Bloois, L. v., Gaillard, P. J.,Danhof, M., Crommelin, D. J. and Boer, A. G. d. 2005. Targeting liposomeswith protein drugs to the blood?brain barrier in vitro . European journal ofpharmaceutical sciences. 25(2), 299-305.
  • Vaysse, L., Burgelin, I., Merlio, J. P. and Arveiler, B. 2000. Improvedtransfection using epithelial cell line-selected ligands and fusogenic peptides.Biochim. Biophys. Acta. 1475(369-376.
  • Vassar, R. 2002. Beta-secretase (BACE) as a drug target for Alzheimer's disease.Adv Drug Deliv Rev. 54(12), 1589-1602.
  • Ulbrich, K., Hekmatara, T., Herbert, E. and Kreuter, J. 2009. Transferrin-andtransferrin-receptor-antibody-modified nanoparticles enable drug deliveryacross the blood?brain barrier (BBB). European Journal of Pharmaceuticsand Biopharmaceutics. 71(2), 251-256.
  • Tseng, H. R., Wang, H., Wang, S., Su, H., Radu, C. G. and Czernin, J. (2010).A supramolecular approach for preparation of size controllable nanoparticles,Google Patents.
  • Thomas, M. and Klibanov, A. M. 2003. Non-viral gene therapy: polycationmediatedDNA delivery. Appl Microbiol Biotechnol. 62(1), 27-34.
  • Thomas, C. E., Ehrhardt, A. and Kay, M. A. 2003. Progress and problems withthe use of viral vectors for gene therapy. Nat Rev Genet. 4(5), 346-358.
  • Temin, H. M. 1961. Mixed infection with two types of Rous sarcoma virus.Virology. 13(158-163.
  • Sverdlov, M., Shajahan, A. N. and Minshall, R. D. 2007. Tyrosinephosphorylation-dependence of caveolae-mediated endocytosis. J Cell MolMed. 11(6), 1239-1250.
  • Suzuki, M., McHugh, J., Tork, C., Shelley, B., Klein, S. M., Aebischer, P. andSvendsen, C. N. 2007. GDNF secreting human neural progenitor cells protectdying motor neurons, but not their projection to muscle, in a rat model offamilial ALS. PLoS One. 2(8), e689.
  • Sukumaran, S. K., Quon, M. J. and Prasadarao, N. V. 2002. Escherichia coli K1internalization via caveolae requires caveolin-1 and protein kinase Calphainteraction in human brain microvascular endothelial cells. J Biol Chem.277(52), 50716-50724.
  • Stolberg, S. G. 1999. The biotech death of Jesse Gelsinger. N Y Times Mag,136-140, 149-150.
  • Stamatovic, S. M., Keep, R. F. and Andjelkovic, A. V. 2008. Brain endothelialcell-cell junctions: how to "open" the blood brain barrier. CurrNeuropharmacol. 6(3), 179-192.
  • Son, S., Hwang do, W., Singha, K., Jeong, J. H., Park, T. G., Lee, D. S. andKim, W. J. 2011. RVG peptide tethered bioreducible polyethylenimine forgene delivery to brain. J Control Release. 155(1), 18-25.
  • Smith, R. A., Miller, T. M., Yamanaka, K., Monia, B. P., Condon, T. P., Hung,G., Lobsiger, C. S., Ward, C. M., McAlonis-Downes, M., Wei, H.,Wancewicz, E. V., Bennett, C. F. and Cleveland, D. W. 2006. Antisenseoligonucleotide therapy for neurodegenerative disease. J Clin Invest. 116(8),2290-2296.
  • Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H.,Verma, I. M. and Masliah, E. 2005. Targeting BACE1 with siRNAsameliorates Alzheimer disease neuropathology in a transgenic model. NatNeurosci. 8(10), 1343-1349.
  • Simonato, M., Bennett, J., Boulis, N. M., Castro, M. G., Fink, D. J., Goins, W.F., Gray, S. J., Lowenstein, P. R., Vandenberghe, L. H., Wilson, T. J., Wolfe,183J. H. and Glorioso, J. C. 2013. Progress in gene therapy for neurologicaldisorders. Nat Rev Neurol. 9(5), 277-291.
  • Sens, P. and Turner, M. S. 2006. Budded membrane microdomains as tensionregulators. Phys Rev E Stat Nonlin Soft Matter Phys. 73(3 Pt 1), 031918.
  • Schnitzer, J. E. 2001. Caveolae: from basic trafficking mechanisms to targetingtranscytosis for tissue-specific drug and gene delivery in vivo. Adv DrugDeliv Rev. 49(3), 265-280.
  • Salahuddin, T. S., Johansson, B. B., Kalimo, H. and Olsson, Y. 1988. Structuralchanges in the rat brain after carotid infusions of hyperosmolar solutions: alight microscopic and immunohistochemical study. Neuropathol ApplNeurobiol. 14(6), 467-482.
  • Safinya, C. R. and Ewert, K. K. 2012. Materials chemistry: Liposomes derivedfrom molecular vases. Nature. 489(7416), 372-374.
  • Ren, W.-h., Chang, J., Yan, C.-h., Qian, X.-m., Long, L.-x., He, B., Yuan, X.-b.,Kang, C.-s., Betbeder, D. and Sheng, J. 2010. Development of transferrinfunctionalized poly (ethylene glycol)/poly (lactic acid) amphiphilic blockcopolymeric micelles as a potential delivery system targeting brain glioma.Journal of Materials Science: Materials in Medicine. 21(9), 2673-2681.
  • Rejman, J., Oberle, V., Zuhorn, I. S. and Hoekstra, D. 2004. Size-dependentinternalization of particles via the pathways of clathrin- and caveolaemediatedendocytosis. Biochem J. 377(Pt 1), 159-169.
  • Rejman, J., Conese, M. and Hoekstra, D. 2006. Gene transfer by means of lipoandpolyplexes: role of clathrin and caveolae-mediated endocytosis. JLiposome Res. 16(3), 237-247.
  • Rejman, J., Bragonzi, A. and Conese, M. 2005. Role of clathrin- and caveolaemediatedendocytosis in gene transfer mediated by lipo- and polyplexes. MolTher. 12(3), 468-474.
  • Ramaswamy, S., McBride, J. L., Han, I., Berry-Kravis, E. M., Zhou, L., Herzog,C. D., Gasmi, M., Bartus, R. T. and Kordower, J. H. 2009. IntrastriatalCERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delaysmotor deficits in a transgenic mouse model of Huntington's disease.Neurobiol Dis. 34(1), 40-50.
  • Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E.,Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., Katz, D., Blaese, R. M.and Oldfield, E. H. 1997. Therapy of malignant brain tumors by intratumoralimplantation of retroviral vector-producing cells. Nat Med. 3(12), 1354-1361.
  • Ragnaill, M. N., Brown, M., Ye, D., Bramini, M., Callanan, S., Lynch, I. andDawson, K. A. 2011. Internal benchmarking of a human blood-brain barriercell model for screening of nanoparticle uptake and transcytosis. Eur JPharm Biopharm. 77(3), 360-367.
  • Rafii, M. S., Baumann, T. L., Bakay, R. A., Ostrove, J. M., Siffert, J., Fleisher,A. S., Herzog, C. D., Barba, D., Pay, M., Salmon, D. P., Chu, Y., Kordower,J. H., Bishop, K., Keator, D., Potkin, S. and Bartus, R. T. 2014. A phase1study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.Alzheimers Dement. 10(5), 571-581.
  • Querfurth, H. W. and LaFerla, F. M. 2010. Alzheimer's disease. N Engl J Med.362(4), 329-344.
  • Qin, Y., Chen, H., Yuan, W., Kuai, R., Zhang, Q., Xie, F., Zhang, L., Zhang, Z.,Liu, J. and He, Q. 2011. Liposome formulated with TAT-modified cholesterolfor enhancing the brain delivery. Int J Pharm. 419(1-2), 85-95.
  • Qin, L. J., Gu, Y. T., Zhang, H. and Xue, Y. X. 2009. Bradykinin-induced bloodtumorbarrier opening is mediated by tumor necrosis factor-alpha. NeurosciLett. 450(2), 172-175.
  • Pun, S. H. 2004. Cyclodextrin-modified polyethylenimine polymers for genedelivery. Bioconjug. Chem. 15(831-840.
  • Polo, S. and Di Fiore, P. P. 2006. Endocytosis conducts the cell signalingorchestra. Cell. 124(5), 897-900.
  • Pelkmans, L. and Helenius, A. 2002. Endocytosis via caveolae. Traffic. 3(5),311-320.
  • Patel, H. M. and Russell, N. J. 1988. Liposomes: from membrane model totherapeutic applications. Biochem Soc Trans. 16(6), 909-910.
  • Parton, R. G. and Simons, K. 2007. The multiple faces of caveolae. Nat RevMol Cell Biol. 8(3), 185-194.
  • Park, T. G., Jeong, J. H. and Kim, S. W. 2006. Current status of polymeric gene180delivery systems. Adv Drug Deliv Rev. 58(4), 467-486.
  • Park, T. E., Kang, B., Kim, Y. K., Zhang, Q., Lee, W. S., Islam, M. A., Kang, S.K., Cho, M. H., Choi, Y. J. and Cho, C. S. 2012. Selective stimulation ofcaveolae-mediated endocytosis by an osmotic polymannitol-based genetransporter. Biomaterials. 33(29), 7272-7281.
  • Park, M. R., Kim, H. W., Hwang, C. S., Han, K. O., Choi, Y. J., Song, S. C.,Cho, M. H. and Cho, C. S. 2008. Highly efficient gene transfer withdegradable poly(ester amine) based on poly(ethylene glycol) diacrylate andpolyethylenimine in vitro and in vivo. J Gene Med. 10(2), 198-207.
  • Park, M. R., Han, K. O., Han, I. K., Cho, M. H., Nah, J. W., Choi, Y. J. and Cho,C. S. 2005. Degradable polyethylenimine-alt-poly(ethylene glycol)copolymers as novel gene carriers. J Control Release. 105(3), 367-380.
  • Pardridge, W. M. 2010. Biopharmaceutical drug targeting to the brain. J DrugTarget. 18(3), 157-167.
  • Pardridge, W. M. 2006. Molecular Trojan horses for blood-brain barrier drugdelivery. Curr Opin Pharmacol. 6(5), 494-500.
  • Nilsson, H., Dragomir, A., Ahlander, A., Johannesson, M. and Roomans, G. M.2007. Effects of hyperosmotic stress on cultured airway epithelial cells. CellTissue Res. 330(2), 257-269.
  • Nie, S. 2010. Understanding and overcoming major barriers in cancernanomedicine. Nanomedicine (Lond). 5(4), 523-528.
  • Nguyen, J., Xie, X., Neu, M., Dumitrascu, R., Reul, R., Sitterberg, J., Bakowsky,U., Schermuly, R., Fink, L., Schmehl, T., Gessler, T., Seeger, W. and Kissel,T. 2008. Effects of cell-penetrating peptides and pegylation on transfectionefficiency of polyethylenimine in mouse lungs. J Gene Med. 10(11), 1236-1246.
  • Neuwelt, E. A., Hill, S. A. and Frenkel, E. P. 1984. Osmotic blood-brain barriermodification and combination chemotherapy: concurrent tumor regression inareas of barrier opening and progression in brain regions distant to barrieropening. Neurosurgery. 15(3), 362-366.
  • Nayak, S. and Herzog, R. W. 2010. Progress and prospects: immune responsesto viral vectors. Gene Ther. 17(3), 295-304.
  • Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E.,Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., Rockenstein,E., Chao, M. V., Koo, E. H., Geschwind, D., Masliah, E., Chiba, A. A. andTuszynski, M. H. 2009. Neuroprotective effects of brain-derivedneurotrophic factor in rodent and primate models of Alzheimer's disease. NatMed. 15(3), 331-337.
  • Moulton, H. M., Hase, M. C., Smith, K. M. and Iversen, P. L. 2003. HIV Tatpeptide enhances cellular delivery of antisense morpholino oligomers.Antisense Nucleic Acid Drug Dev. 13(1), 31-43.
  • Morra, M. 2001. Water in biomaterials surface science. Chichester ; New York,Wiley.
  • Moghimi, S. M., Symonds, P., Murray, J. C., Hunter, A. C., Debska, G. andSzewczyk, A. 2005. A two-stage poly(ethylenimine)-mediated cytotoxicity:implications for gene transfer/therapy. Mol Ther. 11(6), 990-995.
  • Minati, L., Edginton, T., Bruzzone, M. G. and Giaccone, G. 2009. Currentconcepts in Alzheimer's disease: a multidisciplinary review. Am J AlzheimersDis Other Demen. 24(2), 95-121.
  • Mennesson, E., Erbacher, P., Piller, V., Kieda, C., Midoux, P. and Pichon, C.2005. Transfection efficiency and uptake process of polyplexes in humanlung endothelial cells: a comparative study in non-polarized and polarizedcells. J Gene Med. 7(6), 729-738.
  • Medina-Kauwe, L. K., Xie, J. and Hamm-Alvarez, S. 2005. Intracellulartrafficking of nonviral vectors. Gene Ther. 12(24), 1734-1751.
  • McMahon, H. T. and Boucrot, E. 2011. Molecular mechanism andphysiological functions of clathrin-mediated endocytosis. Nat Rev Mol CellBiol. 12(8), 517-533.
  • McIntosh, D. P., Tan, X. Y., Oh, P. and Schnitzer, J. E. 2002. Targetingendothelium and its dynamic caveolae for tissue-specific transcytosis in vivo:a pathway to overcome cell barriers to drug and gene delivery. Proc NatlAcad Sci U S A. 99(4), 1996-2001.
  • McCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J. and Fu, H. 2009.Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed theneurological disease progression in MPS IIIB mice. Gene Ther. 16(11),1340-1352.
  • McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S.R. and Davidson, B. L. 2011. Preclinical safety of RNAi-mediated HTTsuppression in the rhesus macaque as a potential therapy for Huntington'sdisease. Mol Ther. 19(12), 2152-2162.
  • Mazanetz, M. P. and Fischer, P. M. 2007. Untangling tau hyperphosphorylationin drug design for neurodegenerative diseases. Nat Rev Drug Discov. 6(6),464-479.
  • Marks, W. J., Jr., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N.,Vitek, J., Stacy, M., Turner, D., Verhagen, L., Bakay, R., Watts, R., Guthrie,B., Jankovic, J., Simpson, R., Tagliati, M., Alterman, R., Stern, M., Baltuch,G., Starr, P. A., Larson, P. S., Ostrem, J. L., Nutt, J., Kieburtz, K., Kordower,J. H. and Olanow, C. W. 2010. Gene delivery of AAV2-neurturin forParkinson's disease: a double-blind, randomised, controlled trial. LancetNeurol. 9(12), 1164-1172.
  • Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa,F., Mingozzi, F., Bennicelli, J. L., Ying, G. S., Rossi, S., Fulton, A., Marshall,K. A., Banfi, S., Chung, D. C., Morgan, J. I., Hauck, B., Zelenaia, O., Zhu,X., Raffini, L., Coppieters, F., De Baere, E., Shindler, K. S., Volpe, N. J.,Surace, E. M., Acerra, C., Lyubarsky, A., Redmond, T. M., Stone, E., Sun, J.,McDonnell, J. W., Leroy, B. P., Simonelli, F. and Bennett, J. 2009. Agedependenteffects of RPE65 gene therapy for Leber's congenital amaurosis:a phase 1 dose-escalation trial. Lancet. 374(9701), 1597-1605.
  • Madani, F., Lindberg, S., Langel, U., Futaki, S. and Graslund, A. 2011.Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys.2011(414729.
  • Luu, Q. P., Shin, J. Y., Kim, Y. K., Islam, M. A., Kang, S. K., Cho, M. H., Choi,Y. J. and Cho, C. S. 2012. High gene transfer by the osmotic polysorbitolmediatedtransporter through the selective caveolae endocytic pathway. MolPharm. 9(8), 2206-2218.
  • Liu, Y., Li, J., Shao, K., Huang, R., Ye, L., Lou, J. and Jiang, C. 2010. A leptinderived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraftfor brain targeted gene delivery. Biomaterials. 31(19), 5246-5257.
  • Liu, Y., Huang, R., Han, L., Ke, W., Shao, K., Ye, L., Lou, J. and Jiang, C. 2009.Brain-targeting gene delivery and cellular internalization mechanisms formodified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials.30(25), 4195-4202.
  • Liu, K., Wang, X., Fan, W., Zhu, Q., Yang, J., Gao, J. and Gao, S. 2012.Degradable polyethylenimine derivate coupled to a bifunctional peptide R13as a new gene-delivery vector. Int J Nanomedicine. 7(1149-1162.
  • Liu, H., Li, Y., Mozhi, A., Zhang, L., Liu, Y., Xu, X., Xing, J., Liang, X., Ma,G., Yang, J. and Zhang, X. 2014. SiRNA-phospholipid conjugates for geneand drug delivery in cancer treatment. Biomaterials. 35(24), 6519-6533.
  • Li, S., Wang, Y., Zhang, J., Yang, W. H., Dai, Z. H., Zhu, W. and Yu, X. Q. 2011.Biodegradable cross-linked poly(amino alcohol esters) based on LMW PEIfor gene delivery. Mol Biosyst. 7(4), 1254-1262.
  • Li, S. and Huang, L. 2000. Nonviral gene therapy: promises and challenges.Gene Ther. 7(1), 31-34.
  • Li, J., Feng, L., Fan, L., Zha, Y., Guo, L., Zhang, Q., Chen, J., Pang, Z., Wang,Y., Jiang, X., Yang, V. C. and Wen, L. 2011. Targeting the brain with PEGPLGAnanoparticles modified with phage-displayed peptides. Biomaterials.32(21), 4943-4950.
  • LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W.,Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S.,Tatter, S. B., Schwalb, J. M., Poston, K. L., Henderson, J. M., Kurlan, R. M.,Richard, I. H., Van Meter, L., Sapan, C. V., During, M. J., Kaplitt, M. G. andFeigin, A. 2011. AAV2-GAD gene therapy for advanced Parkinson's disease:a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol.10(4), 309-319.
  • Le Roy, C. and Wrana, J. L. 2005. Clathrin- and non-clathrin-mediatedendocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 6(2), 112-126.
  • Kurosaki, T., Morishita, T., Kodama, Y., Sato, K., Nakagawa, H., Higuchi, N.,Nakamura, T., Hamamoto, T., Sasaki, H. and Kitahara, T. 2011.Nanoparticles electrostatically coated with folic acid for effective genetherapy. Mol Pharm. 8(3), 913-919.
  • Kumar, P., Wu, H., McBride, J. L., Jung, K. E., Kim, M. H., Davidson, B. L.,Lee, S. K., Shankar, P. and Manjunath, N. 2007. Transvascular delivery ofsmall interfering RNA to the central nervous system. Nature. 448(7149), 39-43.
  • Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt,C. and Alyautdin, R. 2002. Apolipoprotein-mediated transport ofnanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 10(4),174317-325.
  • Koo, H., Jin, G. W., Kang, H., Lee, Y., Nam, K., Zhe Bai, C. and Park, J. S.2010. Biodegradable branched poly(ethylenimine sulfide) for gene delivery.Biomaterials. 31(5), 988-997.
  • Kong, H. J., Liu, J., Riddle, K., Matsumoto, T., Leach, K. and Mooney, D. J.2005. Non-viral gene delivery regulated by stiffness of cell adhesionsubstrates. Nat Mater. 4(6), 460-464.
  • Kobayashi, D., Zeller, M., Cole, T., Buttini, M., McConlogue, L., Sinha, S.,Freedman, S., Morris, R. G. and Chen, K. S. 2008. BACE1 gene deletion:impact on behavioral function in a model of Alzheimer's disease. NeurobiolAging. 29(6), 861-873.
  • Kiss, A. L. and Botos, E. 2009. Endocytosis via caveolae: alternative pathwaywith distinct cellular compartments to avoid lysosomal degradation? J CellMol Med. 13(7), 1228-1237.
  • Kiss, A. L. 2012. Caveolae and the regulation of endocytosis. Adv Exp MedBiol. 729(14-28.
  • Kircheis, R., Schuller, S., Brunner, S., Ogris, M., Heider, K. H., Zauner, W. andWagner, E. 1999. Polycation-based DNA complexes for tumor-targeted genedelivery in vivo. J Gene Med. 1(2), 111-120.
  • Kim, J. Y., Choi, W. I., Kim, Y. H. and Tae, G. 2013. Brain-targeted delivery ofprotein using chitosan- and RVG peptide-conjugated, pluronic-based nanocarrier.Biomaterials. 34(4), 1170-1178.
  • Khalil, I. A., Kogure, K., Akita, H. and Harashima, H. 2006. Uptake pathwaysand subsequent intracellular trafficking in nonviral gene delivery. PharmacolRev. 58(1), 32-45.
  • Kells, A. P., Eberling, J., Su, X., Pivirotto, P., Bringas, J., Hadaczek, P., Narrow,W. C., Bowers, W. J., Federoff, H. J., Forsayeth, J. and Bankiewicz, K. S.2010. Regeneration of the MPTP-lesioned dopaminergic system afterconvection-enhanced delivery of AAV2-GDNF. J Neurosci. 30(28), 9567-9577.
  • Ke, W., Shao, K., Huang, R., Han, L., Liu, Y., Li, J., Kuang, Y., Ye, L., Lou, J.and Jiang, C. 2009. Gene delivery targeted to the brain using an Angiopepconjugatedpolyethyleneglycol-modified polyamidoamine dendrimer.Biomaterials. 30(36), 6976-6985.
  • Kaur, T. and Slavces, R. (2013). Solid Lipid Nanoparticles: Tuneable Anti-Cancer Gene/Drug Delivery Systems. Novel Gene Therapy Approaches. M.Wei. InTech, InTech.
  • Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. and Gage, F. H. 2003.Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.Science. 301(5634), 839-842.
  • Karkan, D., Pfeifer, C., Vitalis, T. Z., Arthur, G., Ujiie, M., Chen, Q., Tsai, S.,Koliatis, G., Gabathuler, R. and Jefferies, W. A. 2008. A unique carrier for172delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One.3(6), e2469.
  • Karaman, D. S., Desai, D., Senthilkumar, R., Johansson, E. M., Ratts, N., Oden,M., Eriksson, J. E., Sahlgren, C., Toivola, D. M. and Rosenholm, J. M. 2012.Shape engineering vs organic modification of inorganic nanoparticles as atool for enhancing cellular internalization. Nanoscale Res Lett. 7(1), 358.
  • Kapus, A., Szaszi, K., Sun, J., Rizoli, S. and Rotstein, O. D. 1999. Cellshrinkage regulates Src kinases and induces tyrosine phosphorylation ofcortactin, independent of the osmotic regulation of Na+/H+ exchangers. JBiol Chem. 274(12), 8093-8102.
  • Kanwar, J. R., Sriramoju, B. and Kanwar, R. K. 2012. Neurological disordersand therapeutics targeted to surmount the blood-brain barrier. Int JNanomedicine. 7(3259-3278.
  • Kang, Y. S., Ko, Y. G. and Seo, J. S. 2000. Caveolin internalization by heatshock or hyperosmotic shock. Exp Cell Res. 255(2), 221-228.
  • Kanasty, R., Dorkin, J. R., Vegas, A. and Anderson, D. 2013. Delivery materialsfor siRNA therapeutics. Nat Mater. 12(11), 967-977.
  • Jiang, S., Li, Y., Zhang, X., Bu, G., Xu, H. and Zhang, Y. W. 2014. Traffickingregulation of proteins in Alzheimer's disease. Mol Neurodegener. 9(6).
  • Jere, D., Xu, C. X., Arote, R., Yun, C. H., Cho, M. H. and Cho, C. S. 2008.Poly(beta-amino ester) as a carrier for si/shRNA delivery in lung cancer cells.Biomaterials. 29(16), 2535-2547.
  • Jere, D., Jiang, H. L., Kim, Y. K., Arote, R., Choi, Y. J., Yun, C. H., Cho, M. H.and Cho, C. S. 2009. Chitosan-graft-polyethylenimine for Akt1 siRNAdelivery to lung cancer cells. Int J Pharm. 378(1-2), 194-200.
  • Jarraya, B., Boulet, S., Ralph, G. S., Jan, C., Bonvento, G., Azzouz, M., Miskin,J. E., Shin, M., Delzescaux, T., Drouot, X., Herard, A. S., Day, D. M.,Brouillet, E., Kingsman, S. M., Hantraye, P., Mitrophanous, K. A., Mazarakis,N. D. and Palfi, S. 2009. Dopamine gene therapy for Parkinson's disease ina nonhuman primate without associated dyskinesia. Sci Transl Med. 1(2),2ra4.
  • Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J.,Wolfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., Eckert, A.,Staufenbiel, M., Hardeman, E. and Gotz, J. 2010. Dendritic function of taumediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell.142(3), 387-397.
  • Ittner, L. M. and Gotz, J. 2011. Amyloid-beta and tau--a toxic pas de deux inAlzheimer's disease. Nat Rev Neurosci. 12(2), 65-72.
  • Islam, M. A., Yun, C. H., Choi, Y. J., Shin, J. Y., Arote, R., Jiang, H. L., Kang,S. K., Nah, J. W., Park, I. K., Cho, M. H. and Cho, C. S. 2011. Acceleratedgene transfer through a polysorbitol-based transporter mechanism.Biomaterials. 32(36), 9908-9924.
  • Islam, M. A., Shin, J. Y., Yun, C. H., Cho, C. S., Seo, H. W., Chae, C. and Cho,M. H. 2014. The effect of RNAi silencing of p62 using an osmotic170polysorbitol transporter on autophagy and tumorigenesis in lungs of KrasLA1mice. Biomaterials. 35(5), 1584-1596.
  • Islam, M. A., Shin, J. Y., Firdous, J., Park, T. E., Choi, Y. J., Cho, M. H., Yun,C. H. and Cho, C. S. 2012. The role of osmotic polysorbitol-based transporterin RNAi silencing via caveolae-mediated endocytosis and COX-2 expression.Biomaterials. 33(34), 8868-8880.
  • Hwang do, W., Son, S., Jang, J., Youn, H., Lee, S., Lee, D., Lee, Y. S., Jeong, J.M., Kim, W. J. and Lee, D. S. 2011. A brain-targeted rabies virusglycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenicmicroRNA. Biomaterials. 32(21), 4968-4975.
  • Hughes, A. B. 2009. Amino acids, peptides and proteins in organic chemistry.Weinheim, Wiley-VCH.
  • Huang, R.-Q., Qu, Y.-H., Ke, W.-L., Zhu, J.-H., Pei, Y.-Y. and Jiang, C. 2007.Efficient gene delivery targeted to the brain using a transferrin-conjugatedpolyethyleneglycol-modified polyamidoamine dendrimer. The FASEBJournal. 21(4), 1117-1125.
  • Hinson, H. E., Stein, D. and Sheth, K. N. 2011. Hypertonic Saline and MannitolTherapy in Critical Care Neurology. J Intensive Care Med.
  • Hillaireau, H. and Couvreur, P. 2009. Nanocarriers' entry into the cell: relevanceto drug delivery. Cell Mol Life Sci. 66(17), 2873-2896.
  • Hickerson, R. P., Vlassov, A. V., Wang, Q., Leake, D., Ilves, H., Gonzalez-Gonzalez, E., Contag, C. H., Johnston, B. H. and Kaspar, R. L. 2008.Stability study of unmodified siRNA and relevance to clinical use.Oligonucleotides. 18(4), 345-354.
  • Hawkins, R. A., O'Kane, R. L., Simpson, I. A. and Vina, J. R. 2006. Structureof the blood-brain barrier and its role in the transport of amino acids. J Nutr.136(1 Suppl), 218S-226S.
  • Hartsock, A. and Nelson, W. J. 2008. Adherens and tight junctions: structure,function and connections to the actin cytoskeleton. Biochim Biophys Acta.1778(3), 660-669.
  • Hanada, S., Fujioka, K., Inoue, Y., Kanaya, F., Manome, Y. and Yamamoto, K.2014. Cell- Based in vitro Blood-Brain Barrier Model Can Rapidly EvaluateNanoparticles' Brain Permeability in Association with Particle Size andSurface Modification. International Journal of Molecular Sciences. 15(2),1812-1825.
  • Haensler, J. and Szoka, F. C., Jr. 1993. Polyamidoamine cascade polymersmediate efficient transfection of cells in culture. Bioconjug Chem. 4(5), 372-379.
  • Guo, X. and Szoka, F. C., Jr. 2001. Steric stabilization of fusogenic liposomesby a low-pH sensitive PEG--diortho ester--lipid conjugate. Bioconjug Chem.12(2), 291-300.
  • Godbey, W. T., Wu, K. K., Hirasaki, G. J. and Mikos, A. G. 1999. Improvedpacking of poly(ethylenimine)/DNA complexes increases transfectionefficiency. Gene Ther. 6(8), 1380-1388.
  • Godbey, W. T., Wu, K. K. and Mikos, A. G. 2001. Poly(ethylenimine)-mediatedgene delivery affects endothelial cell function and viability. Biomaterials.22(5), 471-480.
  • Gleeson, M. P. 2008. Generation of a set of simple, interpretable ADMET rulesof thumb. J Med Chem. 51(4), 817-834.
  • Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R. and Wixon, J. 2013.
  • Georgieva, J. V., Kalicharan, D., Couraud, P. O., Romero, I. A., Weksler, B.,Hoekstra, D. and Zuhorn, I. S. 2011. Surface characteristics of nanoparticlesdetermine their intracellular fate in and processing by human blood-brainbarrier endothelial cells in vitro . Mol Ther. 19(2), 318-325.
  • Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med.15(2), 65-77.
  • Gastka, M., Horvath, J. and Lentz, T. L. 1996. Rabies virus binding to thenicotinic acetylcholine receptor alpha subunit demonstrated by virus overlayprotein binding assay. J Gen Virol. 77 ( Pt 10)(2437-2440.
  • Gan, C. W. and Feng, S.-S. 2010. Transferrin-conjugated nanoparticles of poly(lactide)-D--tocopheryl polyethylene glycol succinate diblock copolymerfor targeted drug delivery across the blood?brain barrier. Biomaterials.31(30), 7748-7757.
  • Franz, C. K., Federici, T., Yang, J., Backus, C., Oh, S. S., Teng, Q., Carlton, E.,Bishop, K. M., Gasmi, M., Bartus, R. T., Feldman, E. L. and Boulis, N. M.2009. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus1672 is neuroprotective in a rat model of familial ALS. Neurobiol Dis. 33(3),473-481.
  • Forrest, M. L., Gabrielson, N. and Pack, D. W. 2004. Cyclodextrinpolyethylenimineconjugates for targeted in vitro gene delivery. Biotechnol.Bioeng. 89(416-423.
  • Ferrari, A., Pellegrini, V., Arcangeli, C., Fittipaldi, A., Giacca, M. and Beltram,F. 2003. Caveolae-mediated internalization of extracellular HIV-1 tat fusionproteins visualized in real time. Mol Ther. 8(2), 284-294.
  • Fernandez-Carneado, J., Kogan, M. J., Pujals, S. and Giralt, E. 2004.Amphipathic peptides and drug delivery. Biopolymers. 76(2), 196-203.
  • Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M.,Northrop, J. P., Ringold, G. M. and Danielsen, M. 1987. Lipofection: a highlyefficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci US A. 84(21), 7413-7417.
  • Ewert, K. K., Zidovska, A., Ahmad, A., Bouxsein, N. F., Evans, H. M.,McAllister, C. S., Samuel, C. E. and Safinya, C. R. 2010. Cationic liposomenucleicacid complexes for gene delivery and silencing: pathways andmechanisms for plasmid DNA and siRNA. Top Curr Chem. 296(191-226.
  • Edelstein, M. L., Abedi, M. R. and Wixon, J. 2007. Gene therapy clinical trialsworldwide to 2007--an update. J Gene Med. 9(10), 833-842.
  • Du, L., Kayali, R., Bertoni, C., Fike, F., Hu, H., Iversen, P. L. and Gatti, R. A.2011. Arginine-rich cell-penetrating peptide dramatically enhances AMOmediatedATM aberrant splicing correction and enables delivery to brain andcerebellum. Hum Mol Genet. 20(16), 3151-3160.
  • Doran, S. E., Ren, X. D., Betz, A. L., Pagel, M. A., Neuwelt, E. A., Roessler, B.J. and Davidson, B. L. 1995. Gene expression from recombinant viral vectorsin the central nervous system after blood-brain barrier disruption.Neurosurgery. 36(5), 965-970.
  • Dokka, S. and Rojanasakul, Y. 2000. Novel non-endocytic delivery of antisenseoligonucleotides. Adv Drug Deliv Rev. 44(1), 35-49.
  • Di Stefano, A., Iannitelli, A., Laserra, S. and Sozio, P. 2011. Drug deliverystrategies for Alzheimer's disease treatment. Exp Opin Drug Deliv. 8(5), 581-603.
  • Dhaliwal, A., Maldonado, M., Han, Z. and Segura, T. 2010. Differential uptakeof DNA-poly(ethylenimine) polyplexes in cells cultured on collagen andfibronectin surfaces. Acta Biomater. 6(9), 3436-3447.
  • Demeneix, B. and Behr, J. P. 2005. Polyethylenimine (PEI). Non-Viral Vectorsfor Gene Therapy, 2nd Edition: Part 1. 53(217-230.
  • Chung, Y. C., Cheng, T. Y. and Young, T. H. 2011. The role of adenosinereceptor and caveolae-mediated endocytosis in oligonucleotide-mediated165gene transfer. Biomaterials. 32(19), 4471-4480.
  • Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J.,Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S. andAminoff, M. J. 2009. Safety and tolerability of putaminal AADC genetherapy for Parkinson disease. Neurology. 73(20), 1662-1669.
  • Chidlow, J. H., Jr. and Sessa, W. C. 2010. Caveolae, caveolins, and cavins:complex control of cellular signalling and inflammation. Cardiovasc Res.86(2), 219-225.
  • Chi, F., Wang, L., Zheng, X., Jong, A. and Huang, S. H. 2011. Recruitment ofalpha7 nicotinic acetylcholine receptor to caveolin-1-enriched lipid rafts isrequired for nicotine-enhanced Escherichia coli K1 entry into brainendothelial cells. Future Microbiol. 6(8), 953-966.
  • Chen, S., Ge, X., Chen, Y., Lv, N., Liu, Z. and Yuan, W. 2013. Advances withRNA interference in Alzheimer's disease research. Drug Des Devel Ther.7(117-125.
  • Castanotto, D. and Rossi, J. J. 2009. The promises and pitfalls of RNAinterference-based therapeutics. Nature. 457(7228), 426-433.
  • Carver, L. A. and Schnitzer, J. E. 2003. Caveolae: mining little caves for newcancer targets. Nat Rev Cancer. 3(8), 571-581.
  • Canton, I. and Battaglia, G. 2012. Endocytosis at the nanoscale. Chem Soc Rev.16441(7), 2718-2739.
  • Cantin, E. M. and Rossi, J. J. 2007. Molecular medicine: entry granted. Nature.448(7149), 33-34.
  • Campbell, R. N. 2008. Gene therapy and cancer research focus. New York,Nova Biomedical Books.
  • Brun, E., Carriere, M. and Mabondzo, A. 2012. In vitro evidence ofdysregulation of blood-brain barrier function after acute and repeated/longtermexposure to TiO(2) nanoparticles. Biomaterials. 33(3), 886-896.
  • Brookmeyer, R., Johnson, E., Ziegler-Graham, K. and Arrighi, H. M. 2007.Forecasting the global burden of Alzheimer's disease. Alzheimers Dement.3(3), 186-191.
  • Broadwell, R. D. 1989. Transcytosis of macromolecules through the bloodbrainbarrier: a cell biological perspective and critical appraisal. ActaNeuropathol. 79(2), 117-128.
  • Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D.,Demeneix, B. and Behr, J. P. 1995. A versatile vector for gene andoligonucleotide transfer into cells in culture and in vivo: polyethylenimine.Proc Natl Acad Sci U S A. 92(16), 7297-7301.
  • Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici,M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., Greenblatt, J. J.,Rosenberg, S. A., Klein, H., Berger, M., Mullen, C. A., Ramsey, W. J., Muul,163L., Morgan, R. A. and Anderson, W. F. 1995. T lymphocyte-directed genetherapy for ADA- SCID: initial trial results after 4 years. Science. 270(5235),475-480.
  • Benjaminsen, R. V., Mattebjerg, M. A., Henriksen, J. R., Moghimi, S. M. andAndresen, T. L. 2013. The possible "proton sponge " effect ofpolyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther.21(1), 149-157.
  • Barreto, J. A., O'Malley, W., Kubeil, M., Graham, B., Stephan, H. and Spiccia,L. 2011. Nanomaterials: applications in cancer imaging and therapy. AdvMater. 23(12), H18-40.
  • Balazs, D. A. and Godbey, W. 2011. Liposomes for use in gene delivery. J DrugDeliv. 2011(326497.
  • Arvanitakis, Z., Tuszynski, M. H., Bakay, R., Arends, D., Potkin, S., Bartus, R.and Bennett, D. 2007. Interim data from a phase 1 clinical trial of AAV-NGF(CERE-110) gene delivery in Alzheimer's disease. Neurology. 68(12), A233-A234.
  • Arote, R., Kim, T. H., Kim, Y. K., Hwang, S. K., Jiang, H. L., Song, H. H., Nah,162J. W., Cho, M. H. and Cho, C. S. 2007. A biodegradable poly(ester amine)based on polycaprolactone and polyethylenimine as a gene carrier.Biomaterials. 28(4), 735-744.
  • Arote, R. B., Hwang, S. K., Yoo, M. K., Jere, D., Jiang, H. L., Kim, Y. K., Choi,Y. J., Nah, J. W., Cho, M. H. and Cho, C. S. 2008. Biodegradable poly(esteramine) based on glycerol dimethacrylate and polyethylenimine as a genecarrier. J Gene Med. 10(11), 1223-1235.
  • Arima, H., Kihara, F., Hirayama, F. and Uekama, K. 2001. Enhancement ofgene expression by polyamidoamine dendrimer conjugates with [alpha]-,[beta]-, and [gamma]-cyclodextrins. Bioconjug. Chem. 12(476-484.
  • Apodaca, G. 2002. Modulation of membrane traffic by mechanical stimuli. AmJ Physiol Renal Physiol. 282(2), F179-190.
  • Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S. and Wood, M. J. 2011.Delivery of siRNA to the mouse brain by systemic injection of targetedexosomes. Nat Biotechnol. 29(4), 341-345.
  • Akiyama, T. and Ogawara, H. 1991. Use and specificity of genistein as inhibitorof protein-tyrosine kinases. Methods Enzymol. 201(362-370.
  • Akinc, A., Thomas, M., Klibanov, A. M. and Langer, R. 2005. Exploringpolyethylenimine-mediated DNA transfection and the proton spongehypothesis. J Gene Med. 7(5), 657-663.
  • Abbott, N. J., Ronnback, L. and Hansson, E. Carver, L. A. 2006. Nat RevNeurosci. 7(1), 41-53.
  • Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R. and Begley, D.J. 2010. Structure and function of the blood-brain barrier. Neurobiol Dis.37(1), 13-25.